Education
About Us
Working with TipRanks
Follow Us
Maravai Lifesciences Holdings, Inc. (MRVI)
:MRVI
RESEARCH TOOLSreports
MRVI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.67 - $9.60
Previous CloseN/A
Volume457.32K
Average Volume (3M)1.69M
Market Cap
$656.28M
Enterprise Value$650.90M
Total Cash (Recent Filing)$269.91M
Total Debt (Recent Filing)$371.08M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Nov 05, 2025EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding144,677,780
10 Day Avg. Volume1,996,381
30 Day Avg. Volume1,690,524
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue3.02
Enterprise Value/Gross Profit10.36
Enterprise Value/Ebitda-2.29
Forecast
1Y Price Target
$4.75Price Target Upside89.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Leadership ExperienceBernd Brust brings more than 30 years of global life sciences leadership experience, which can provide valuable insights and direction for Maravai LifeSciences.
Operational GrowthThe base Nucleic Acid Production (NAP) business posted quarter-over-quarter growth for the first time since 4Q23.
Strategic VisionRaj Asarpota's familiarity with the new CEO and major shareholder GTCR is expected to be beneficial as the company develops a new strategic vision.
Bears Say
Financial UncertaintyThe company has not updated or reaffirmed its financial guidance, indicating potential uncertainty in its financial outlook.
Product Mix ChallengeAdjusted gross margin came in below expectations due to an unfavorable product mix in the NAP segment.
Revenue DeclineMaravai's non-COVID business has declined year-over-year for nine consecutive quarters, indicating persistent challenges in its key end-markets.
Maravai Lifesciences Holdings News
MRVI FAQ
What was Maravai Lifesciences Holdings, Inc.’s price range in the past 12 months?
Maravai Lifesciences Holdings, Inc. lowest stock price was $1.67 and its highest was $9.60 in the past 12 months.
What is Maravai Lifesciences Holdings, Inc.’s market cap?
Maravai Lifesciences Holdings, Inc.’s market cap is $656.28M.
When is Maravai Lifesciences Holdings, Inc.’s upcoming earnings report date?
Maravai Lifesciences Holdings, Inc.’s upcoming earnings report date is Nov 05, 2025 which is in 76 days.
How were Maravai Lifesciences Holdings, Inc.’s earnings last quarter?
Maravai Lifesciences Holdings, Inc. released its earnings results on Aug 11, 2025. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.074 by -$0.006.
Is Maravai Lifesciences Holdings, Inc. overvalued?
According to Wall Street analysts Maravai Lifesciences Holdings, Inc.’s price is currently Undervalued.
Does Maravai Lifesciences Holdings, Inc. pay dividends?
Maravai Lifesciences Holdings, Inc. does not currently pay dividends.
What is Maravai Lifesciences Holdings, Inc.’s EPS estimate?
Maravai Lifesciences Holdings, Inc.’s EPS estimate is -0.08.
How many shares outstanding does Maravai Lifesciences Holdings, Inc. have?
Maravai Lifesciences Holdings, Inc. has 144,677,780 shares outstanding.
What happened to Maravai Lifesciences Holdings, Inc.’s price movement after its last earnings report?
Maravai Lifesciences Holdings, Inc. reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.074. Following the earnings report the stock price went up 30.583%.
Which hedge fund is a major shareholder of Maravai Lifesciences Holdings, Inc.?
Currently, no hedge funds are holding shares in MRVI
Maravai Lifesciences Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.75 (89.24% Upside)
$4.75 (89.24% Upside)
Blogger Sentiment
Bullish
MRVI Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 675.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 7.8%
Last 30 Days ▼ 7.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.83%
12-Months-Change
Fundamentals
Return on Equity
-55.41%
Trailing 12-Months
Asset Growth
-38.04%
Trailing 12-Months
Company Description
Maravai Lifesciences Holdings, Inc.
Maravai Lifesciences Holdings (MRVI) is a leading provider of life science reagents and services to researchers and biotech companies. The company operates in sectors such as biopharmaceutical development and manufacturing, diagnostics, and genomics. Its core products include nucleic acid production, biologics safety testing, and protein detection products, which support the development of new drugs, diagnostics, and therapeutics.
MRVI Company Deck
MRVI Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights significant restructuring efforts and growth in the Biologics Safety Testing segment. However, these positives are countered by substantial revenue declines, increased net losses, and challenges in the U.S. market. While there are promising strategic initiatives and growth prospects in China, the financial challenges and restructuring costs present notable concerns.View all MRVI earnings summariesMRVI Revenue Breakdown
77.79% Nucleic Acid Production
22.21% Biologics Safety Testing
MRVI Stock 12 Month Forecast
Average Price Target
$4.75
▲(89.24% Upside)
Technical Analysis
Cogent Biosciences
―
Immunome
―
Pharming Group
―
LENZ Therapeutics
―
Bicara Therapeutics Inc.
―
Ownership Overview
Currently, No data available
---